Dylan M. Glatt

Dylan M. Glatt

Auto-generated profile, based on publicly available information

Dylan M. Glatt

423andMe Therapeutics, South San Francisco, California

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in American Journal of Pharmaceutical Education
Verified
Journal Article
Closed access
JMJacqueline E. McLaughlin
Jacqueline E. McLaughlin
LGLaToya M. Griffin
LaToya M. Griffin
DEDenise A. Esserman
Denise A. Esserman
CDChristopher A. Davidson
Christopher A. Davidson
DGDylan M. Glatt
Dylan M. Glatt
RMRussell J. Mumper
Russell J. Mumper
Objective. To determine whether “flipping” a traditional basic pharmaceutics course delivered synchronously to 2 satellite campuses would improve student academic performance, engagement, and perception.Design. In 2012, the basic pharmaceutics course was flipped and delivered to 22 satellite students on 2 different campuses. Twenty-five condensed, recorded course lectures were placed on the course Web site for students to watch prior to class. Scheduled class periods were dedicated to participating in active-learning exercises. Students also completed 2 course projects, 3 midterm examinations, 8 graded quizzes, and a cumulative and comprehensive final examination.Assessment. Results of a survey administered at the beginning and end of the flipped course in 2012 revealed an increase in students’ support for learning content prior to class and using class time for more applied learning (p=0.01) and in the belief that learning key foundational content prior to coming to class greatly enhanced in-class learni...

7 March 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DVDenis R Beckford Vera
Denis R Beckford Vera
CSChristof C Smith
Christof C Smith
LBLisa M Bixby
Lisa M Bixby
DGDylan M Glatt
Dylan M Glatt
SDStuart S Dunn
Stuart S Dunn
MPMatthew C Parrott
Matthew C Parrott
The ability to non-invasively monitor tumor-infiltrating T cells in vivo could provide a powerful tool to visualize and quantify tumor immune infiltrates. For non-invasive evaluations in vivo, an anti-CD3 mAb was modified with desferrioxamine (DFO) and radiolabeled with zirconium-89 (Zr-89 or 89Zr). Radiolabeled 89Zr-DFO-anti-CD3 was tested for T cell detection using positron emission tomography (PET) in both healthy mice and mice bearing syngeneic bladder cancer BBN975. In vivo PET/CT and ex vivo biodistribution demonstrated preferential accumulation and visualization of tracer in the spleen, thymus, lymph nodes, and bone marrow. In tumor bearing mice, 89Zr-DFO-anti-CD3 demonstrated an 11.5-fold increase in tumor-to-blood signal compared to isotype control. Immunological profiling demonstrated no significant change to total T cell count, but observed CD4+ T cell depletion and CD8+ T cell expansion to the central and effector memory. This was very encouraging since a high CD8+ to CD4+ T cell ratio has already been associated with better patient prognosis. Ultimately, this anti-CD3 mAb allowed for in vivo imaging of homeostatic T cell distribution, and more specifically tumor-infiltrating T cells. Future applications of this radiolabeled mAb against CD3 could include prediction and monitoring of patient response to immunotherapy.

28 April 2016 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
DGDylan M. Glatt
Dylan M. Glatt
DVDenis R. Beckford Vera
Denis R. Beckford Vera
MPMatthew C. Parrott
Matthew C. Parrott
JLJ. Christopher Luft
J. Christopher Luft
SBS. Rahima Benhabbour
S. Rahima Benhabbour
RMRussell J. Mumper
Russell J. Mumper

18 September 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
DGDylan M. Glatt
Dylan M. Glatt
DVDenis R. Beckford Vera
Denis R. Beckford Vera
SPShamit S. Prabhu
Shamit S. Prabhu
RMRussell J. Mumper
Russell J. Mumper
JLJ. Christopher Luft
J. Christopher Luft
MPMatthew C. Parrott
Matthew C. Parrott

1 January 2025 in Cancer Research Communications
Verified
Journal Article
Open access
Shivaani KummarShivaani Kummar
Shivaani Kummar
ARAlbiruni Razak
Albiruni Razak
SLScott Laurie
Scott Laurie
DGDylan M. Glatt
Dylan M. Glatt
SKSariah Kell
Sariah Kell
DRDrew Rasco
Drew Rasco
Purpose: In this phase 1 portion of a first-in-human phase 1/2a study (NCT05199272), 23ME-00610 was evaluated in participants with advanced solid malignancies to determine its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD). Exploratory biomarkers were evaluated to examine potential correlates of efficacy and safety. Patients and Methods: Eligible participants (≥18 years) were administered 23ME-00610 intravenously every 3 weeks (Q3W) using an accelerated titration design followed by a traditional 3 + 3 design, with an initial dose level of 2 mg. Results: Twenty-eight participants were enrolled across seven cohorts and received a median of four cycles of 23ME-00610. No treatment-related serious adverse events (AE) were observed, and the maximum tolerated dose was not reached. Overall, the PK of 23ME-00610 was linear and dose proportional for doses ≥60 mg, with a median terminal half-life of 13 days at 1,400 mg. Peripheral saturation of CD200R1 was observed for doses ≥60 mg. Immune-related AEs, including rash, pruritus, and hypothyroidism, were predicted by phenome-wide association studies and observed for doses ≥60 mg. A confirmed partial response was observed in a participant with well-differentiated pancreatic neuroendocrine cancer whose tumor was among those with the highest tumor CD200 expression. Conclusions: 23ME-00610 has mild-to-moderate on-target AEs and PK/PD consistent with tumor target saturation and dosing every 3 weeks. The trend for clinical benefit in participants with tumor CD200 expression suggests that 23ME-00610 inhibits CD200R1 signaling and may reverse CD200-mediated immune evasion. Based on PK/PD, safety, and preliminary antitumor activity, 1,400 mg Q3W was selected as the dose for further study. Significance: Genome-wide association studies (GWAS) of the 23andMe genetic database identified CD200R1 as a promising therapeutic target for cancer. This phase 1 study of 23ME-00610, a CD200R1 antagonist IgG1, showed acceptable safety and tolerability, PK supporting Q3W dosing, and PD and preliminary clinical activity supporting an initial recommended phase 2 dose of 1,400 mg.

15 January 2025
Verified
Other
Open access
Shivaani KummarShivaani Kummar
Shivaani Kummar
ARAlbiruni Razak
Albiruni Razak
SLScott Laurie
Scott Laurie
DGDylan M. Glatt
Dylan M. Glatt
SKSariah Kell
Sariah Kell
DRDrew Rasco
Drew Rasco
Purpose:In this phase 1 portion of a first-in-human phase 1/2a study (NCT05199272), 23ME-00610 was evaluated in participants with advanced solid malignancies to determine its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD). Exploratory biomarkers were evaluated to examine potential correlates of efficacy and safety.Patients and Methods:Eligible participants (≥18 years) were administered 23ME-00610 intravenously every 3 weeks (Q3W) using an accelerated titration design followed by a traditional 3 + 3 design, with an initial dose level of 2 mg.Results:Twenty-eight participants were enrolled across seven cohorts and received a median of four cycles of 23ME-00610. No treatment-related serious adverse events (AE) were observed, and the maximum tolerated dose was not reached. Overall, the PK of 23ME-00610 was linear and dose proportional for doses ≥60 mg, with a median terminal half-life of 13 days at 1,400 mg. Peripheral saturation of CD200R1 was observed for doses ≥60 mg. Immune-related AEs, including rash, pruritus, and hypothyroidism, were predicted by phenome-wide association studies and observed for doses ≥60 mg. A confirmed partial response was observed in a participant with well-differentiated pancreatic neuroendocrine cancer whose tumor was among those with the highest tumor CD200 expression.Conclusions:23ME-00610 has mild-to-moderate on-target AEs and PK/PD consistent with tumor target saturation and dosing every 3 weeks. The trend for clinical benefit in participants with tumor CD200 expression suggests that 23ME-00610 inhibits CD200R1 signaling and may reverse CD200-mediated immune evasion. Based on PK/PD, safety, and preliminary antitumor activity, 1,400 mg Q3W was selected as the dose for further study.Significance:Genome-wide association studies (GWAS) of the 23andMe genetic database identified CD200R1 as a promising therapeutic target for cancer. This phase 1 study of 23ME-00610, a CD200R1 antagonist IgG1, showed acceptable safety and tolerability, PK supporting Q3W dosing, and PD and preliminary clinical activity supporting an initial recommended phase 2 dose of 1,400 mg.